Chen Fang, PharmD, RPh

We’ve developed a comprehensive fact sheet for clinicians to share with patients and caregivers on the differences in diagnosis and treatment for occipital neuralgia vs migraine.

Researchers sought to analyze the effect of lemborexant on total sleep time, REM sleep, and nonREM sleep in patients with insomnia and comorbid mild OSA.

Study authors evaluated whether donanemab was superior to aducanumab on the percentage of participants with amyloid plaque clearance after 6 months of therapy in patients with early symptomatic AD.

Study authors conducted a global, open-label, phase 3 study to report the safety and efficacy of ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD).

In a study presented at ACTRIMS Forum 2023, researchers assessed the efficacy of treatment regimens on disability outcomes of patients with NMOSD- and MOGAD-optic neuritis and myelitis.

Researchers assessed the efficacy, safety, and tolerability of glatiramer acetate (GA) Depot when given every 4 weeks in patients with relapsing forms of MS.

A case study presented at the 2022 CMSC Annual Meeting reviews a 47-year-old male patient who experienced relapsing steroid-responsive encephalomyelitis after SARS-CoV-2 infection and subsequent COVID-19 infection.

Presenting at CMSC 2022, researchers assessed the risk for reproductive and embryofetal toxicity in women exposed to ponesimod during pregnancy.

Researchers reported results from an interim analysis of an ongoing open-label extension to study the safety and efficacy of adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

New data about Pfizer COVID-19 efficacy after the first dose suggests high efficacy, raising questions about potential alternative dosing schedules.

We speak with Mildred Solomon, EdD, President of the Hastings Center and Professor of Global Health and Social Medicine at Harvard Medical School, where she directs the school’s Fellowship in Bioethics, about the COVID-19 pandemic, health equity, and vaccine distribution.

Johnson & Johnson released interim analysis of its phase 3 EMSEMBLE trial for Ad.26.COV2, and provided more insight on overall protection in various countries, variant protection, and clinical outcomes.

Anthony Fauci, MD, discusses public trust in science, vaccine progress, and vaccine facilitation as the United States heads toward a new phase of the pandemic.

George Abraham, MD, offers insight into where the United States currently stands with regard to the COVID-19 pandemic, vaccine development, barriers to care in various patient populations, and the evolving roles of infectious disease specialists.